P53, a tumor suppressor gene that is mutated and inactivated in the vast majority of cancers, has often been described as the "guardian of the genome" because of its protective effects against cancer.
Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...
In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...
Phase I Trials in Pediatric Oncology: Perceptions of Pediatricians From the United Kingdom Children’s Cancer Study Group and the Pediatric Oncology Group PURPOSE: The loss of p53 function is a ...
"It's going against dogma: The field thinks p53 mutant automatically is stable" and produces metastasis. "p53 mutational status in tumors may dictate the response to therapy in more ways than ...
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged cellular tumor antigen p53 (TP53) (Tyr220Cys mutant) stabilizers reported to be useful for the treatment of cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback